tbuckley/cabot-search huggingface dataset:
Natural Killer Cell Expression of Natural Cytotoxicity Receptors Determines Relapse Risk in Elderly Patients with Acute Myeloid Leukemia Receiving Immunotherapy with Histamine Dihydrochloride and Interleukin-2
Authors: Anna Martner, Anna Rydström, Rebecca E Riise, Johan Aurelius, Mats L Brune, Robin Foa, Kristoffer Hellstrand, Fredrik B Thorén
Journal: Blood (2014)
Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or Diffuse Large B-Cell Lymphoma: Preliminary Report of a Phase 1/2 Study
Authors: Luis Fayad, Hemant Patel, Gregor Verhoef, Mitchell R. Smith, Peter W.M. Johnson, Myron S. Czuczman, Bertrand Coiffier, Georg Hess, Eva Gine, Anjali Advani, Fritz Offner, Erik R. Vandendries, Mark Shapiro, Nam H. Dang
Journal: Blood (2008)
Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL)
Authors: Jonathan Friedberg, Daruka Mahadevan, JungAh Jung, Daniel O. Persky, Izidore S Lossos, Hadi Danaee, Xiaofei Zhou, E Jane Leonard, Steven H. Bernstein
Journal: Blood (2011)
Kinetics and Apoptotic Profile of Circulating Endothelial Cells as an Indicator of Response to Treatment in Acute Myeloid Leukemia Patients.
Authors: Agnieszka Wierzbowska, Tadeusz Robak, Anna Krawczynska, Agnieszka Pluta, Agata Wrzesien-Kus, Barbara Cebula, Piotr Smolewski
Journal: Blood (2006)
PTU-042 The Incremental Benefit of Video Capsule Endoscopy after Magnetic Resonance Enterography (MRE) In Patients with Suspected Small Bowel Crohn’s Disease
Authors: T Archer, S Samuel, L Simmonds, R Sikafi, P Plichta
Journal: Gut (2016)

<h3>Introduction</h3> Video Capsule Endoscopy (VCE) has the unique ability to visualise the small intestinal mucosa, which traditionally is difficult to reach with a standard endoscope. The indications for this test are primarily to investigate the small bowel (SB) in patients with Crohn’s Disease (CD) and to evaluate the SB for causes of Iron Deficiency Anaemia (IDA). Despite the high diagnostic yield with VCE, one of its main drawbacks is its low specificity in patients with inflammatory bowel disease (IBD). In a prospective blinded 4 way comparison study, capsule endoscopy had a sensitivity of 83% and a specificity of 53%.<sup>1</sup> We intended to evaluate the additional benefit of VCE in our patient cohort with particular emphasis on those patients who had MRE prior to their VCE as part of their work up for IBD. <h3>Methods</h3> Patients who had VCE in Nottingham University Hospitals NHS Trust between January 1<sup>st</sup> 2014 and January 1<sup>st</sup> 2016 were included. Patient data including demographics, previous investigations and the treating physician’s interpretation of results and resultant change in management, from these investigations, were abstracted on to an excel spreadsheet. <h3>Results</h3> 171 patients were included, of whom 148 were adults and 87 were female. The commonest indication was IDA [n = 70 (41%)]. Diarrhoea and IBD were the second most common indication with 63 patients (37%). SB abnormalities were detected in 96 patients, of which 48 had not previously been visualised on alternative investigations. This changed management in 28 patients (16%) based on the abnormalities detected. There was one complication observed; the capsule remained in the stomach stuck within rugal folds and requiring endoscopic retrieval. 44 patients with suspected CD had MRE prior to capsule endoscopy. Abnormalities were seen in 20 of these capsule endoscopies, of which 14 had not been seen in previous investigations. However, only in 5 patients (10%) did these positive capsule findings facilitate a change in their disease management. Of the 63 patients who were investigated for IBD or diarrhoea, 15 patients were diagnosed with CD in light of the VCE findings. However, of these, only 4 patients had had a change in management, of whom 3 had had findings consistent with CD already demonstrated on MRE. <h3>Conclusion</h3> VCE is a useful and safe diagnostic test to detect SB pathology. This modality assisted management in 16% of our patient cohort. However, in the setting of IBD it appears that VCE rarely has findings that lead to a change in management over and above MRE. <h3>Reference</h3> 1 Solem CA, Loftus EV, Jr, Fletcher JG, Baron TH, Gostout CJ, Petersen BT, <i>et al</i>. Small-bowel imaging in Crohn’s disease: a prospective, blinded, 4-way comparison trial. <i>Gastrointest Endosc</i> 2008;<b>68</b>(2):255–66. <h3>Disclosure of Interest</h3> None Declared
Groups need selves, but which selves? Dual selves in groups and the downsides of individuation
Authors: Mark P Healey
Journal: Behavioral and Brain Sciences (2016)

Abstract It may be true that “groups need selves,” as Baumeister et al. contend. However, certain types of selfhood and too much selfhood can both be detrimental to group functioning. I draw on theory and research on dual selves in work groups and teams to outline boundary conditions to the hypothesis that emphasizing individual selves yields positive effects for groups.
A Maintenance Therapy with Differentiating Agents and Low-Dose Chemotherapy Increases Remission Duration and Survival in High Risk AML and MDS Patients.
Authors: Dario Ferrero, Chiara Dellacasa, Margherita Bonferroni, Mariella Grasso, Elisabetta Campa, Valentina Giai, Mariella Genuardi, Mario Boccadoro
Journal: Blood (2005)
Impact of Combining Targeted Agents with High-Dose Cytarabine-Based Induction Chemotherapy on Acute Myeloid Leukemia Outcomes: The M.D. Anderson Cancer Center Experience
Authors: Alfonso Quintás-Cardama, Hagop M. Kantarjian, Guillermo Garcia-Manero, Mark Brandt, Stefan Faderl, Sherry Pierce, Gautam Borthakur, Farhad Ravandi, Jorge E. Cortes
Journal: Blood (2011)
A Novel PF4-Heparin Microbead Assay and Plasma Protein Biomarker Profiling for Improved Diagnosis of Heparin Induced Thrombocytopenia.
Authors: Resmi Ravindran, Imran Khan, Robert Gosselin, Ted Wun, V.V. Krishnan, Paul Luciw, Kim Janatpour
Journal: Blood (2007)
Genetic Engineering of Donor T Cells for BMT Immunotherapy: Expression of TRAIL and PLZF Selectively Enhances GVT and Abrogates Gvhd
Authors: Arnab Ghosh, Amanda M. Holland, Yildirim Dogan, Nury Yim, Uttam K. Rao, Lauren F. Young, Odette M. Smith, Robert Jenq, Il-Kang Na, Jennifer Tsai, Olaf Penack, Alan M. Hanash, Martin G. Sauer, Derek Sant'Angelo, Michel Sadelain, Marcel R.M. van den Brink
Journal: Blood (2010)
Prevalence and clinical associations of PTEN loss in non-small cell lung carcinoma (NSCLC) patients (pts) of the European Thoracic Oncology Platform (ETOP) Lungscape cohort
Authors: A. Soltermann, U. Rulle, O. Dafni, E. Verbeken, E. Thunnissen, A. Warth, R. Cheney, A. Sejda, E.-J. Speel, L. Bille Madsen, D. Nonaka, A. Navarro, I. Sansano, A. Marchetti, S. Finn, R. Kammler, K. Schulze, L. Bubendorf, R.A. Stahel, O.B.O. Lungscape
Journal: Annals of Oncology (2016)
Rearrangement Patterns of Igs and bcl2/IgH and Clinical Significance in Follicular Lymphoma.
Authors: J. Martinez-Lopez, A. Rivero, C. Montalban, J. de la Serna, A. Fernandez-Sevilla, J. Paz, M. Canales, R. Ona, P. Sanchez-Godoy, R. Martinez, S. Grande, P. Martinez-Sanchez, R. Ayala, Jose F. Tomas
Journal: Blood (2006)
Valproic Acid Induces Apoptosis in Chronic Lymphocytic Leukemia Cells through Activation of the Death Receptor Pathway and Potentiates TRAIL Response.
Authors: Laurence Lagneaux, Nicolas Gillet, Alain Delforge, Marielle Dejeneffe, Basile Stamatopoulos, Martine Massy, Nathalie Meuleman, Alain Kentos, Luc Willems, Dominique Bron
Journal: Blood (2006)
Technique Standards for Skin Lesion Imaging
Authors: Chinmayee Katragadda, Anna Finnane, H. Peter Soyer, Ashfaq A. Marghoob, Allan Halpern, Josep Malvehy, Harald Kittler, Rainer Hofmann-Wellenhof, Dennis Da Silva, Ivo Abraham, Clara Curiel-Lewandrowski
Journal: JAMA Dermatology (2016)

Variability in the metrics for image acquisition at the total body, regional, close-up, and dermoscopic levels impacts the quality and generalizability of skin images. Consensus guidelines are indicated to achieve universal imaging standards in dermatology.To achieve consensus among members of the International Skin Imaging Collaboration (ISIC) on standards for image acquisition metrics using a hybrid Delphi method.Delphi study with 5 rounds of ratings and revisions until relative consensus was achieved. The initial set of statements was developed by a core group (CG) on the basis of a literature review and clinical experience followed by 2 rounds of rating and revisions. The consensus process was validated by an extended group (EG) of ISIC members through 2 rounds of scoring and revisions. In all rounds, respondents rated the draft recommendations on a 1 (strongly agree) to 5 (strongly disagree) scale, explained ratings of less than 5, and optionally provided comments. At any stage, a recommendation was retained if both mean and median rating was 4 or higher.The initial set of 45 items (round 1) was expanded by the CG to 56 variants in round 2, subsequently reduced to 42 items scored by the EG in round 3, yielding an EG set of 33 recommendations (rounds 4 and 5): general recommendation (1 guideline), lighting (5), background color (3), field of view (3), image orientation (8), focus/depth of field (3), resolution (4), scale (3), color calibration (2), and image storage (1).This iterative process of ratings and comments yielded a strong consensus on standards for skin imaging in dermatology practice. Adoption of these methods for image standardization is likely to improve clinical practice, information exchange, electronic health record documentation, harmonization of clinical studies and database development, and clinical decision support. Feasibility and validity testing under real-world clinical conditions is indicated.
AB0729 Baseline Levels of CTX-II and Glucosyl-Galactosyl-Pyridinoline in Patients Wih Early Psoriasic Arthritis: Association with Disease Severity,Disability, Quality-of-Life, Biological Treatment Required and Progression of Joint Destruction at 5 Years of Follow Up
Authors: E. Trujillo, M. Garcia, H. Sanchez, L. Exposito, A. Monroy, M.D.M. Trujillo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Although many efforts have been made to identify Psoriasic Arthritis (PsA)-specific biomarkers, none of the putative ones identified so far has resulted in a clinically relevant outcome and patient benefit. In other diseases of the joints, elevated levels of urinary CTX-II (C-telopeptide fragments of type II collagen) and Glc-Gal-PYD (glucosyl-galactosyl-pyridinoline) have been associated with progression of damage. <h3>Objectives</h3> To analyze the association between the baseline levels of urinary CTX-II and Glc-Gal-PYD in patient with early PsA with disability, quality of life, biological treatment required and radiological damage at 5 years of follow up. <h3>Methods</h3> We included 36 patients who came to the service with some of the suggestive information of PsA and who later completed five years of follow-up and they fulfill nowadays PsA according to classification of psoriatic arthritis (CASPAR) criteria. Urine samples were taken from all patients attending for the first time with suspected early PsA. Urinary excretion of CTX-II was determined by immunoassay (ELISA) (ng/ml). Urinary excretion of Glc-Gal-PYD was determined by High performance liquid chromatography (HPLC). Because urinary levels were not normally distributed, all data were transformed into logarithms for analysis. Association analysis was performed with the following five variables at 5 years: Disease Severity for the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): mild, moderate and severe. Health Assessment Questionnaire (HAQ). Study Short Form 36 (SF-36). Anti-TNF therapy: Yes/No. Sharp-van Der Heijde modified scoring method for PsA. <h3>Results</h3> Baseline levels of urinary excretion of CTX-II and Glc-Gal-PYD in patients presenting for the first time with suspected early SpA were significantly higher in those who had HAQ and SF-36 scores significantly worse, required biological treatment and in those due to moderate and severe disease severity at five years of follow up. In a multivariable linear regression analysis, Baseline levels of urinary excretion of CTX-II and Glc-Gal-PYD in patients presenting for the first time with suspected early SpA were an important predictor of worse radiological score at the age of 5 (erosions, joint space narrowing, (subluxation, ankylosis, gross osteolysis, and pencil in cup phenomena). <h3>Conclusions</h3> Baseline levels of urinary excretion of CTX-II and Glc-Gal-PYD in patients with early SpA may be a prognostic biomarker since in our series it was associated with worse disease severity, disability, quality-of-life and progression of joint destruction at 5 years of follow up. <h3>Disclosure of Interest</h3> None declared
Celecoxib-loaded PEA microspheres as an auto regulatory drug-delivery system after intra-articular injection
Authors: Maarten Janssen, Ufuk Tan Timur, Nina Woike, Tim J.M. Welting, Guy Draaisma, Marion Gijbels, Lodewijk W. van Rhijn, George Mihov, Jens Thies, Pieter J. Emans
Journal: Journal of Controlled Release (2016)
PTH-158 The Potential Financial Benefit of Using CT Colonography in Selected Patients Referred on a Suspected Colorectal Cancer Pathway: Abstract PTH-158 Table 1
Authors: T Garvey, C Kane, A Plumb, R Vega, E Seward
Journal: Gut (2016)

<h3>Introduction</h3> Colonoscopy effectively excludes bowel cancer as a cause for a patient’s symptoms but may result in cross-sectional imaging further along the pathway and CT colonography (CTC) may address both issues. We propose to pilot a straight to test (STT) model where patients 75 years and over undergo CTC as routine, and assessed the potential financial benefit of this. <h3>Methods</h3> Data from 2 week wait referrals for suspected colorectal cancer to UCLH between June 12<sup>th</sup> 2014 to November 17<sup>th</sup> 2014 was analysed retrospectively from hospital systems. Data was collected from the time of referral until discharge from the pathway. Using the NHS tariffs (to nearest £) for each investigation/procedure, we calculated the potential financial benefit by directly comparing actual costs incurred versus the potential costs using the STT model. <h3>Results</h3> In total, 505 patients were referred, with 477 of these patients sent for further tests; 353 referred for endoscopy (332 colonoscopy), and 110 referred for CTC. The average age of patients for endoscopy was 59.3 years versus 71 years for CTC. In the endoscopy group, 46 patients were aged 75 or older (13%). Table 1 details the costs incurred (excluding staging CT). Had all 46 patients had a CTC initially, this would have resulted in a cost of £10948 and follow up costs for endoscopy would have been as per further procedures as in Table 1 (£1860 + £4690 + £309), resulting in a total of £17807. In the 5 month period analysed, a potential saving of £3735 using the STT model, representing a potential annual saving of £8964. <h3>Conclusion</h3> Potentially ≈ £9000 per annum could be saved using the STT model proposed, and could also have eased pressure on endoscopy capacity. Further increases on financial savings include careful referral to endoscopy after CTC. Extra-colonic organ review is offered by CTC and may reduce the need for further imaging, and account for those requring CT post endoscopy. A third of patients are estimated to require endoscopy after CTC in the STT model, and although this may increase patient distress and inconvenience due to multiple tests, it allows targeted therapeutic colonoscopy. STT has also been demonstrated to reduce outpatient clinic appointments, thereby reducing costs not analysed in this analysis. However, a trained nurse is required which involves expenditure but is associated with greater patient satisfaction. <h3>Disclosure of Interest</h3> None Declared
Stimulation of Platelet Production in Healthy Volunteers by a Novel Pegylated Peptide-Based Thrombopoietin (TPO) Receptor Agonist.
Authors: Dirk Cerneus, K. Brown, R. Harris, D. End, C. Molloy, E. Yurkow, H. Koblish, C. Franks, M. Moolenaar, K. Burggraaf
Journal: Blood (2005)
The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma
Authors: Nathan H Fowler, Ranjana H Advani, Jeff Sharman, Sonali M. Smith, Jesse McGreivy, Lori Kunkel, Vina Troung, Cathy Zhou, Thomas E. Boyd
Journal: Blood (2012)
Adaptive Immunotherapy with Autologous CD25-Depleted and CD3/CD28-Costimulated T-Cells Enhances Lymphocyte Recovery after Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma.
Authors: Charalambos Andreadis, Bruce L. Levine, Sunita D. Nasta, Julio Cotte, Zhaohui Zheng, Andrea Cannon, Kathleen Wiley, Lisa H. Downs, Bernadette Diccion, Elizabeth Veloso, Carl H. June, Stephen J. Schuster
Journal: Blood (2006)
The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast
Authors: G. Pruneri, M. Lazzeroni, V. Bagnardi, G.B. Tiburzio, N. Rotmensz, A. DeCensi, A. Guerrieri-Gonzaga, A. Vingiani, G. Curigliano, S. Zurrida, F. Bassi, R. Salgado, G. Van den Eynden, S. Loi, C. Denkert, B. Bonanni, G. Viale
Journal: Annals of Oncology (2016)
Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States
Authors: Qiushi Chen, Nitin Jain, Turgay Ayer, William G. Wierda, Christopher R. Flowers, Susan M. O’Brien, Michael J. Keating, Hagop M. Kantarjian, Jagpreet Chhatwal
Journal: Journal of Clinical Oncology (2017)

Purpose Oral targeted therapies represent a significant advance for the treatment of patients with chronic lymphocytic leukemia (CLL); however, their high cost has raised concerns about affordability and the economic impact on society. Our objective was to project the future prevalence and cost burden of CLL in the era of oral targeted therapies in the United States. Methods We developed a simulation model that evaluated the evolving management of CLL from 2011 to 2025: chemoimmunotherapy (CIT) as the standard of care before 2014, oral targeted therapies for patients with del(17p) and relapsed CLL from 2014, and for first-line treatment from 2016 onward. A comparator scenario also was simulated where CIT remained the standard of care throughout. Disease progression and survival parameters for each therapy were based on published clinical trials. Results The number of people living with CLL in the United States is projected to increase from 128,000 in 2011 to 199,000 by 2025 (55% increase) due to improved survival; meanwhile, the annual cost of CLL management will increase from $0.74 billion to $5.13 billion (590% increase). The per-patient lifetime cost of CLL treatment will increase from $147,000 to $604,000 (310% increase) as oral targeted therapies become the first-line treatment. For patients enrolled in Medicare, the corresponding total out-of-pocket cost will increase from $9,200 to $57,000 (520% increase). Compared with the CIT scenario, oral targeted therapies resulted in an incremental cost-effectiveness ratio of $189,000 per quality-adjusted life-year. Conclusion The increased benefit and cost of oral targeted therapies is projected to enhance CLL survivorship but can impose a substantial financial burden on both patients and payers. More sustainable pricing strategies for targeted therapies are needed to avoid financial toxicity to patients.
FRI0214 Six-Year Retention Rate of Abatacept in Rheumatoid Arthritis: A Multicentric Retrospective Analysis
Authors: E.G. Favalli, C. Botsios, C. Bazzani, B. Raffainer, G. Ciancio, A. Giollo, A. Marchesoni, R. Gorla, C. Caimmi, A. Becciolini, C. Crotti, S. Piantoni, M. Biggioggero, A. Carletto
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Abatacept (ABT) short-term efficacy and safety profile in the treatment of rheumatoid arthritis (RA) is well established and supported by randomised controlled trials. However, data on ABT long-term effects are still lacking and reported drug survival analyses are often limited to no more than 2-year follow-up. <h3>Objectives</h3> The aim of the study is to evaluate in a real-life scenario the overall 6-year retention rate of ABT in the treatment of RA and to compare its survival rate as first or second line biotherapy. <h3>Methods</h3> Data were retrospectively extracted from six local registries including all RA patients treated with ABT between January 2008 and April 2015. The analysis was limited to patients treated with ABT as first or second line biologic agent. The 6-year retention rate was calculated by Kaplan-Meier method and the comparative risk for discontinuation between the two lines of treatment was compared by a stratified log-rank test. <h3>Results</h3> 236 RA patients (78.5% female, mean age [± standard deviation, SD] 57.6 [±12.7] years, mean disease duration 14.3 [±13.4] years, positive rheumatoid factor 82.2%, positive anti-citrullinated peptide antibodies 71.1%, mean DAS28 5.19 [±1.2]) were retrospectively enrolled. 83 patients were treated with ABT as first-line biotherapy, whereas 153 were second-line users. The overall retention rate was 63.7% at 3 years and 61.8% at 6 years. The 6-year retention rate was significantly higher in the first-line compared with the second-line therapy group (68% and 61.8%, respectively; p=0.04). Overall, ABT was discontinued in 69 (29.2%) patients. Twenty-one (8.9%) patients (4 first-line and 17 second-line users, p=0.15) withdrew ABT because of adverse events, whereas 41 (17.4%) patients (10 first-line and 31 second-line users, p=0.1508) stopped the therapy because of primary or secondary inefficacy. Seven (2.7%) patients discontinued ABT because of other reasons (i.e. lost at follow-up, pregnancy and remission) and were excluded from the retention analysis. <h3>Conclusions</h3> In our multicentric experience the 6-year retention rate of both first and second line ABT was about 60%. Used as first line ABT showed a significantly higher survival on treatment compared with the second line. Moreover, ABT demonstrated an overall favourable safety profile, with a very low occurrence of adverse events leading to discontinuation. <h3>Disclosure of Interest</h3> None declared
Pharmacokinetics of Cyclophosphamide Metabolites Influence Outcome in Patients with β-Thalassemia Major Undergoing Allogeneic HSCT
Authors: Poonkuzhali Balasubramanian, Salamun Desire, John C Panetta, Kavitha M Lakshmi, Ezhilpavai Mohanan, Auro Viswabandya, Biju George, Vikram Mathews, Mammen Chandy, Alok Srivastava
Journal: Blood (2011)
Distinction of Inherited from Acquired Thrombotic Thrombocytopenic Purpura Applying the Cone and Plate(Let) Analyzer.
Authors: Boris Shenkman, Ulrich Budde, Dorothea Angerhaus, Reinhard Schneppenheim, Aharon Lubetsky, Naphtali Savion, Uri Seligsohn, David Varon
Journal: Blood (2004)
Eculizumab Is an Effective Treatment for Atypical Hemolytic Uremic Syndrome in Pediatric and Adult Patients with or without Identified Genetic Complement Mutations or Complement Factor H Autoantibodies
Authors: Spero R Cataland, Thorsten Feldkamp, Camille L. Bedrosian, John Kincaid, Enrico E. Minetti
Journal: Blood (2014)
Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML)
Authors: Xiaomeng Huang, Sebastian Schwind, Bo Yu, Jiuxia Pang, Ramasamy Santhanam, Kenneth K. Chan, Ramiro Garzon, William Blum, Clara D. Bloomfield, Shujun Liu, Danilo Perrotti, Robert J. Lee, John C. Byrd, Natarajan Muthusamy, L. James Lee, Guido Marcucci
Journal: Blood (2011)